Synthesis and SAR development of novel P2X 7 receptor antagonists for the treatment of pain: Part 1

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 12, 2011, Pages 3805-3808

  Matasi, Julius J ^a   Brumfield, Stephanie ^a   Tulshian, Deen ^a   Czarnecki, Michael ^a   Greenlee, William ^a   Garlisi, Charles G ^a   Qiu, Hongchen ^a   Devito, Kristine ^a   Chen, Shu Cheng ^a   Sun, Youngliang ^a   Bertorelli, Rosalia ^a   Geiss, William ^b   Le, Van Duc ^b   Martin, Gregory S ^b   Vellekoop, Samuel A ^b   Haber, James ^b   Allard, Melissa L ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

Inflammatory pain; Neuropathic pain; P2X 7; Purine derivatives

Indexed keywords

2 PIPERIDYLPYRIDINE DERIVATIVE; 2 TRIFLUOROMETHYL 4 PYRIDYL DERIVATIVE; 4 CYANO 3 FLUOROPHENYL DERIVATIVE; 5 PYRIDYL ISOMER; BENZENE DERIVATIVE; GABAPENTIN; NAPROXEN; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM TRANSPORT; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; EXERCISE; HUMAN; HYPERALGESIA; IC 50; ISOMER; NEUROPATHIC PAIN; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION;

ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PAIN; PURINERGIC P2 RECEPTOR ANTAGONISTS; RATS; RECEPTORS, PURINERGIC P2X7; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS; RODENTIA;

EID: 79957836035     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.04.034     Document Type: Article

References (23)

1. Collo, G.; Neidhart, S.; Kawashima, E.; Kosco-Vibois, M.; Norht, R. A.; Buell, G. Neuropharmacology 1997, 36, 1277.
2. DiVirgilio, F.; Vishwanath, V.; Ferrari, D. Handb. Exp. Pharmacol. 2001, 151, 355.
3. Sim, J. A.; Young, M. T.; Sung, H.-Y.; North, R. A.; Surprenant, A. J. Neurosci. 2004, 24, 6307.
4. Pelegrin, P.; Surprenant, A. EMBO J. 2006, 25, 5071.
5. Donnelly-Roberts, D. L.; Jarvis, M. F. Br. J. Pharmacol 2007, 151, 571.
6. Ferrari, D.; Pizzirani, C.; Adinlfi, E.; Lemoli, R. M.; Curti, A.; Idzko, M.; Panther, E.; DiVirgilio, F. J. Immunol. 2006, 176, 3877.
7. Carroll, W. A.; Donnelly-Roberts, D.; Jarvis, M. F. Purinergic Signalling 2009, 5, 63.
8. Burnstock, G. Pharmacol. Rev. 2006, 58, 58.
9. Samad, D. A.; Moore, K. A.; Sapirstein, A.; Billett, S.; Poole, S.; Allchorne, A.; Bonventre, J. V.; Woolf, C. J. Nature (London, UK) 2001, 410, 471.
10. Wolf, C. J.; Allchorne, A.; Safieh-Garabedian, B.; Poole, S. Br. J. Pharmacol. 1997, 121, 417.
11. Labasi, J. M.; Petrushova, N.; Donovan, C.; McCurdy, S.; Lira, P.; Payette, M. M.; Brissette, W.; Wicks, J. R.; Audoly, L.; Gabel, C. A. J. Immunol. 2002, 168, 6436.
12. Chessell, I. P.; Hatcher, J. P.; Bountra, C.; Michael, A. D.; Hughes, J. P.; Green, P.; Egerton, J.; Murfin, M.; Richardson, J.; Peck, W. L.; Grahames, C. B. A.; Casula, M. A.; Yiangou, Y.; Birch, R.; Anand, P.; Bell, G. N. Pain 2005, 114, 386.
13. Nelson, D. W.; Gregg, R. J.; Kort, M. E.; Perez-Medrano, A.; Voigh, E. A.; Wang, Y.; Grayson, G.; Namovic, M. T.; Donnelly-Roberts, D. L.; Niforatos, W.; Honor, P.; Jarvis, M. F.; Faltynek, C. R.; Carroll, W. A. J. Med. Chem. 2006, 49, 3659.
14. Honore, P.; Donnelly-Roberts, D.; Namovic, M. T.; Hsieh, G.; Zhu, C. Z.; Mikusa, J. P.; Hernandez, G.; Zhong, C.; Gauvin, D. M.; Chandran, P.; Harris, R.; Perez-Medrano, A.; Carroll, W. A.; Marsh, K.; Sullivan, J.; Faltynek, C. R.; Jarvis, M. F. J. Pharmacol. Exp. Ther. 2006, 319, 1376.
15. Carroll, W. A.; Kelvin, D. M.; Perez-Medrano, A.; Florjancic, A. S.; Wang, Y.; Donnelly-Roberts, D. L.; Namovic, M. T.; Grayson, G.; Honore, P.; Jarvis, M. F. Bioorg. Med. Chem. Lett. 2007, 17, 4044.
16. Cheewatrakoolpong, B.; Gilchrest, H.; Anthes, J. C.; Greenfeder, S. Biochem. Biophys. Res. Commun 2005, 332, 17. Each compound was tested at least twice and the average values are provided. For this assay, the average coefficient of variance was 29%.
17. Compounds were assessed for their ability to inhibit ATP-mediated IL-1β production in LPS-stimulated whole blood cultures. Compounds were added to whole blood for 30 min followed by LPS for 3 h. ATP was added and IL-1β concentrations were measured using commercially available ELISA kits. Each compound was tested at least twice and the average values are provided. For this assay, the average coefficient of variance was 37%.
18. Mei, H.; Korfmacher, W.; Morrison, R. AAPS J. 2006, 8, E493.
19. Bove, S. E.; Calcaterra, S. L.; Brooker, R. M.; Huber, C. M.; Guzman, R. E.; Juneau, P. L.; Schrier, D. J.; Kilgore, K. S. Osteoarthritis Cartilage 2003, 11, 821.
20. (a) Bennett, G. J.; Xie, Y. K. Pain 1988, 33, 87;
21. (b) Hunter, J. C.; Gogas, K. R.; Hedley, L. R.; Jacobson, L. O.; Kassotakis, L.; Thompson, J.; Fontana, D. J. Eur. J. Pharmacol. 1997, 324, 153.
22. (a) An alternative synthesis of desired targets shown in Scheme 3 and referenced in (a) Boyle, C. D.; Xu, R.; Asberom, T.; Chackalamannil, S.; Clader, J. W.; Greenlee, W. J.; Guzik, H.; Hu, Y.; Hu, Z.; Lankin, C. M. Bioorg. Med. Chem. Lett. 2005, 15, 2365;
23. (b) Tulshian, D.; Geiss, W. B.; Martin, G. S.; Le, V.; Haber, J. C.; Matasi, J. J.; Czarniecki, M. F.; and Cooke, S. N. PCT Int. Appl. (2008), WO 2009002423 A2 20081231. (Chemical Equation Presented)